EU/3/19/2190
Table of contents
About
On 21 August 2019, orphan designation EU/3/19/2190 was granted by the European Commission to Eiger Biopharmaceuticals Europe Limited, United Kingdom, for peginterferon lambda-1a for the treatment of hepatitis D virus infection.
The sponsorship was transferred to Eigerbio Europe Limited, Ireland, in October 2019.
Key facts
Active substance |
Peginterferon lambda-1a
|
Disease / condition |
Treatment of hepatitis D virus infection
|
Date of first decision |
21/08/2019
|
Outcome |
Positive
|
EU designation number |
EU/3/19/2190
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Eigerbio Europe Limited
1 Castlewood Avenue
Rathmines
Dublin 6, D06 H685
Ireland
Tel. +1 650 272 6138
E-mail: info@eigerbio.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: